Research graph
References from Comparative effectiveness and safety of first-line anti-TNF, vedolizumab, and ustekinumab in biologic-naïve Crohn’s disease: Analysis from a real-world cohort. Local targets link to admitted publications; unresolved targets remain external evidence.
ACG clinical guideline: management of Crohn’s disease in adults
10.14309/ajg.0000000000003465 · 2025 · External reference
Ustekinumab as induction and maintenance therapy for Crohn’s disease
10.1056/nejmoa1602773 · 2016 · External reference
Vedolizumab as induction and maintenance therapy for Crohn’s disease
10.1056/nejmoa1215739 · 2013 · External reference
Real-world clinical effectiveness and safety of vedolizumab and Adalimumab in biologic-naive patients with Crohn’s disease: results from the EVOLVE study
10.1097/mcg.0000000000002056 · 2025 · External reference
Comparative effectiveness of infliximab vs Ustekinumab for endoscopic and transmural remission in biologic Naïve Crohn’s disease
2026 · External reference
Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-naïve or anti-TNF-exposed Crohn’s disease: a multicenter cohort study
10.1016/j.eclinm.2023.102337 · 2023 · External reference
Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with vedolizumab or ustekinumab: findings from SOJOURN
10.1186/s12876-023-02723-5 · 2023 · External reference
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
10.1016/s0140-6736(22)00688-2 · 2022 · External reference
Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
10.1016/s0140-6736(22)00466-4 · 2022 · External reference
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn’s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
10.1016/s0140-6736(24)01762-8 · 2024 · External reference
Efficacy and Safety of Guselkumab subcutaneous induction and maintenance in participants with moderately to severely active Crohn’s disease: results from the phase 3 GRAVITI Study
10.1053/j.gastro.2025.02.033 · 2025 · External reference
A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn’s disease. The cross Pennine study II
10.1111/apt.16742 · 2022 · External reference
Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn’s disease: real-life cohort from a tertiary referral center
10.1097/meg.0000000000002411 · 2022 · External reference
Comparative efficacy and rapidity of action for infliximab vs Ustekinumab in biologic Naïve Crohn’s disease
10.1016/j.cgh.2021.04.006 · 2022 · External reference
Real-world comparative effectiveness of Ustekinumab vs Anti-TNF in Crohn’s disease with propensity score adjustment: induction phase results from the prospective, observational RUN-CD study
10.1093/ibd/izac271 · 2023 · External reference
Comparative real-world outcomes between ustekinumab, infliximab, and adalimumab in bio-naïve and bio-experienced Crohn’s disease patients: a retrospective multicenter study
10.1186/s12876-024-03403-8 · 2024 · External reference
Comparative effectiveness of Ustekinumab and Anti-TNF agent as first-line biological therapy in luminal Crohn’s disease: a retrospective study from 2 referral centers
10.1093/ibd/izac167 · 2023 · External reference
Real-world effectiveness of Vedolizumab vs anti-TNF in biologic-naïve Crohn’s disease patients: a 2-year propensity-score-adjusted analysis from the VEDOIBD-study
10.1093/ibd/izad138 · 2024 · External reference
Effectiveness and treatment persistence of Vedolizumab compared to anti-Tumour necrosis factor-α in patients with Crohn’s disease: a systematic literature review and meta-analysis. united
10.1002/ueg2.12705 · 2025 · External reference
Biologic therapy for inflammatory bowel disease: real-world comparative effectiveness and impact of drug sequencing in 13 222 patients within the UK IBD BioResource
10.1093/ecco-jcc/jjad203 · 2024 · External reference
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial
10.1136/gutjnl-2013-304984 · 2014 · External reference
Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease
10.1177/1756284820979765 · 2020 · External reference
Fecal Calprotectin correlates more closely with the simple endoscopic score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI
10.1038/ajg.2009.545 · 2010 · External reference
STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD
10.1053/j.gastro.2020.12.031 · 2021 · External reference
Normalization of fecal calprotectin within 12 months of diagnosis is associated with reduced risk of disease progression in patients with crohn’s disease
10.1016/j.cgh.2020.08.022 · 2021 · External reference
Infliximab maintenance therapy for fistulizing Crohn’s disease
10.1056/nejmoa030815 · 2004 · External reference
ECCO Guidelines on therapeutics in Crohn’s disease: medical treatment
10.1093/ecco-jcc/jjae091 · 2024 · External reference
Meta-analysis: persistence of advanced therapies in the treatment of inflammatory bowel disease
10.1111/apt.18006 · 2024 · External reference
Superior treatment persistence with ustekinumab in Crohn’s disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the persistence Australian national IBD cohort (PANIC) study
10.1111/apt.16436 · 2021 · External reference
Comparative Safety and Effectiveness of Biologic Therapy for Crohn’s Disease: a CA-IBD Cohort Study
10.1016/j.cgh.2022.10.029 · 2023 · External reference
Comparative safety of advanced therapies for Crohn disease
10.1001/jamanetworkopen.2025.57922 · 2026 · External reference
Upadacitinib induction and maintenance therapy for Crohn’s disease
10.1056/nejmoa2212728 · 2023 · External reference
